Within the hematologic cancer patient cohort there was a striking increase in the levels of the chemokines CCL2, CCL3, CCL4, CXCL8, and the cytokine IL-1β, in the Severe-Death group compared to the Mild group (Figure 3A). Here, CCL3 is linked to hematopoietic and lymphoid cell neoplasm.